Moderna (MRNA) was not the cure for the biotech industry, which has broadly sold off this quarter. Moderna upsized its offering to raise $604 million at a record-shattering $8.1 billion valuation. It is the largest biotech IPO by both...read more
DiaMedica Therapeutics, a Phase 2 biotech targeting acute ischemic stroke and chronic kidney disease, raised $16.4 million by offering 4.1 million shares at $4, the low end of the range of $4 to $5. The company offered 100,000 more shares than expected. At the...read more
Four companies plan to raise $689 million during the week ahead. Biotech giant Moderna (MRNA) continues this year's boom of large biotech IPOs. Developing a platform of messenger RNA, Moderna is raising $500 million at an $8.0 billion...read more
No companies went public this past week, during the post-Thanksgiving lull. Three healthcare deals joined the IPO calendar for next week. Messenger RNA...read more
US IPO Weekly Recap: Biggest biotech breaks in 3-IPO week
Moderna (MRNA) was not the cure for the biotech industry, which has broadly sold off this quarter. Moderna upsized its offering to raise $604 million at a record-shattering $8.1 billion valuation. It is the largest biotech IPO by both...read more
Micro-cap vascular biotech DiaMedica Therapeutics prices IPO at $4 low end
DiaMedica Therapeutics, a Phase 2 biotech targeting acute ischemic stroke and chronic kidney disease, raised $16.4 million by offering 4.1 million shares at $4, the low end of the range of $4 to $5. The company offered 100,000 more shares than expected. At the...read more
US IPO Week Ahead: Largest-ever biotech IPO Moderna leads 4-deal week
Four companies plan to raise $689 million during the week ahead. Biotech giant Moderna (MRNA) continues this year's boom of large biotech IPOs. Developing a platform of messenger RNA, Moderna is raising $500 million at an $8.0 billion...read more
US IPO Weekly Recap: A quiet week ahead of 2018's final stretch
No companies went public this past week, during the post-Thanksgiving lull. Three healthcare deals joined the IPO calendar for next week. Messenger RNA...read more